Phase 2 Lung Cancer Trial, Recruiting NCT03965234 Sponsor: Roswell Park Cancer Institute Condition: Lung Cancer
Back to Lung Cancer

Phase 2 Lung Cancer Trial, Recruiting

NCT03965234
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have cancer that has spread (metastasized) to the lungs, and it is specifically one of these three types: soft tissue sarcoma, osteosarcoma, or colorectal cancer
  • You are generally able to carry out daily activities and care for yourself (your doctor rates your overall health and activity level as reasonably good)
  • Your blood counts and kidney function are within acceptable ranges, including healthy enough levels of red blood cells, white blood cells, and platelets (confirm with trial site)
  • Your kidney function meets a minimum level as measured by a specific blood/urine test (confirm with trial site)
  • Your lung function tests show your lungs are working at least 50% as well as expected for someone your age and size
  • Your blood oxygen level while resting and moving around is above a minimum safe level
  • You are able to walk at least 50% of the expected distance in a six-minute walking test
  • You do not feel severely short of breath, as measured by a standard breathing difficulty scale
  • Your original (primary) cancer tumor is considered stable or under control, as judged by your doctor
  • The surgeon has confirmed that the procedure used in this trial is technically possible for you
  • The lung metastases can be completely removed or destroyed, based on review of your scans
  • If you are able to become pregnant, you must agree to use reliable contraception during the study
  • You are willing and able to sign an informed consent form after having the study explained to you

Who may not be able to join:

  • You have received chemotherapy or radiation therapy within the past 4 weeks (or 6 weeks for certain specific chemotherapy drugs), or you are still experiencing side effects from previous treatment
  • You have cancer that has spread to the brain
  • You have had a serious allergic reaction or cannot tolerate the chemotherapy drugs used in this procedure
  • You are currently pregnant or breastfeeding
  • You are unwilling or unable to follow the requirements of the study
  • Your lung metastases cannot be completely removed or destroyed based on your imaging scans
  • You have received another experimental treatment within the past 30 days
  • You have severe nerve damage in your hands or feet (severe peripheral neuropathy)
  • You have any other condition that your doctor believes makes it unsafe or unsuitable for you to take part in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Kenneth Seastedt, Roswell Park Cancer Institute

Phone: 716-845-2300

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Roswell Park Cancer Institute
Registry
ClinicalTrials.gov
Start date
16 July 2020
Est. completion
25 May 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of local toxicities (Phase I); Recommended phase II dose (Phase I); Local recurrence (Phase II)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov